NCT06774027 - Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions

HER2-negative Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast CancerHR+ HER2 Breast CancerMetastatic Triple Negative Breast CancersMetastatic Triple-Negative Breast Carcinoma

Interventions

PROCEDURE

Specimen collection

Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis

DRUG

Non-Investigational Antibody-Drug Conjugates (ADC)

ADC given under usual care for the treatment of cancer

OTHER

Medical Record Review

Prospective and retrospective medical chart reviews will be conducted to obtain data for analysis.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco